Per- and polyfluoroalkyl substance plasma concentrations and metabolomic markers of type 2 diabetes in the Diabetes Prevention Program trial.

Biomarkers Diabetes Mellitus, Type 2 / prevention & control Environmental Pollutants Humans Metabolomics Research Design
Metabolomics PFAS Type 2 diabetes

Journal

International journal of hygiene and environmental health
ISSN: 1618-131X
Titre abrégé: Int J Hyg Environ Health
Pays: Germany
ID NLM: 100898843

Informations de publication

Date de publication:
03 2021
Historique:
received: 10 09 2020
revised: 24 11 2020
accepted: 02 12 2020
pubmed: 22 12 2020
medline: 26 10 2021
entrez: 21 12 2020
Statut: ppublish

Résumé

Per- and polyfluoroalkyl substances (PFAS) are widely used chemicals, some of which have been linked to type 2 diabetes. We tested whether PFAS concentrations were cross-sectionally associated with metabolites previously shown to predict incident type 2 diabetes using the Diabetes Prevention Program (DPP), a trial of individuals at high risk of type 2 diabetes. We evaluated 691 participants enrolled in the DPP with baseline measures of 10 PFAS (including total perfluorooctanesulfonic acid (PFOS), total perfluorooctanoic acid (PFOA), and Sb-PFOA [branched isomers of PFOA]) and 77 metabolites. We used log Sb-PFOA was associated with the largest number of tested metabolites (29 of 77). Each doubling in Sb-PFOA was associated with higher leucine (β = 0.07 [95%CI: 0.02, 0.11] SD) and lower glycine (-0.08 [95%CI: 0.03, -0.13] SD). Each doubling of either total PFOA or n-PFOA was associated with -0.13 [95%CI: 0.04, -0.22] SD lower glycine. PFOA and Sb-PFOA were positively associated with multiple triacylglycerols and diacylglycerols, and total PFOS, total PFOA, and Sb-PFOA were positively associated with phosphatidylethanolamines. PFAS concentrations are associated with metabolites linked to type 2 diabetes (particularly amino acid, glycerolipid and glycerophospholipid pathways). Further prospective research is needed to test whether these metabolites mediate associations of PFAS and type 2 diabetes.

Sections du résumé

BACKGROUND
Per- and polyfluoroalkyl substances (PFAS) are widely used chemicals, some of which have been linked to type 2 diabetes. We tested whether PFAS concentrations were cross-sectionally associated with metabolites previously shown to predict incident type 2 diabetes using the Diabetes Prevention Program (DPP), a trial of individuals at high risk of type 2 diabetes.
METHODS
We evaluated 691 participants enrolled in the DPP with baseline measures of 10 PFAS (including total perfluorooctanesulfonic acid (PFOS), total perfluorooctanoic acid (PFOA), and Sb-PFOA [branched isomers of PFOA]) and 77 metabolites. We used log
RESULTS
Sb-PFOA was associated with the largest number of tested metabolites (29 of 77). Each doubling in Sb-PFOA was associated with higher leucine (β = 0.07 [95%CI: 0.02, 0.11] SD) and lower glycine (-0.08 [95%CI: 0.03, -0.13] SD). Each doubling of either total PFOA or n-PFOA was associated with -0.13 [95%CI: 0.04, -0.22] SD lower glycine. PFOA and Sb-PFOA were positively associated with multiple triacylglycerols and diacylglycerols, and total PFOS, total PFOA, and Sb-PFOA were positively associated with phosphatidylethanolamines.
CONCLUSIONS
PFAS concentrations are associated with metabolites linked to type 2 diabetes (particularly amino acid, glycerolipid and glycerophospholipid pathways). Further prospective research is needed to test whether these metabolites mediate associations of PFAS and type 2 diabetes.

Identifiants

DOI: 10.1016/j.ijheh.2020.113680 PMID: 33348273 PMC: PMC8630734
pubmed: 33348273
pii: S1438-4639(20)30626-X
doi: 10.1016/j.ijheh.2020.113680
pmc: PMC8630734
mid: NIHMS1657005
pii:
doi:

Substances chimiques

Biomarkers 0
Environmental Pollutants 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

113680

Subventions

Organisme : NIDDK NIH HHS
ID : U01 DK048412
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048375
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048434
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048413
Pays : United States
Organisme : NIEHS NIH HHS
ID : K23 ES024803
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002534
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048339
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048514
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048468
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048387
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048404
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES024765
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048489
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048437
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048407
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES030101
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048397
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048381
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES007069
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048443
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048380
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK048400
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier GmbH. All rights reserved.

Références

Environ Int. 2019 May;126:445-453
pubmed: 30844580
Int J Hyg Environ Health. 2018 Aug;221(7):1054-1060
pubmed: 30056006
Diabetes Care. 2000 Nov;23(11):1619-29
pubmed: 11092283
Nutrients. 2019 Jun 16;11(6):
pubmed: 31208147
J Chromatogr A. 2011 Apr 15;1218(15):2133-7
pubmed: 21084089
Epidemiology. 2004 Sep;15(5):615-25
pubmed: 15308962
Diabetes Care. 2018 Dec;41(12):2617-2624
pubmed: 30327364
Diabetes Care. 2013 Feb;36(2):342-7
pubmed: 23033247
Environ Int. 2019 Aug;129:343-353
pubmed: 31150976
Risk Anal. 2008 Apr;28(2):251-69
pubmed: 18419647
PLoS One. 2011;6(6):e20862
pubmed: 21677784
Environ Int. 2020 Apr;137:105217
pubmed: 32086073
Environ Toxicol Pharmacol. 2005 Jan;19(1):57-70
pubmed: 21783462
BMC Bioinformatics. 2008 Feb 25;9:114
pubmed: 18298808
Metabolomics. 2019 Jun 21;15(7):95
pubmed: 31227916
Nat Rev Endocrinol. 2014 Dec;10(12):723-36
pubmed: 25287287
J Agric Food Chem. 2007 Apr 18;55(8):3203-10
pubmed: 17381114
Environ Int. 2019 Dec;133(Pt A):105160
pubmed: 31518937
J Expo Sci Environ Epidemiol. 2019 Mar;29(2):196-205
pubmed: 30185940
Diabetes. 2019 Dec;68(12):2337-2349
pubmed: 31582408
Environ Sci Technol. 2015 Oct 6;49(19):11849-58
pubmed: 26333069
Sci Rep. 2016 Apr 01;6:23963
pubmed: 27032815
Environ Health Perspect. 2018 Mar 01;126(3):037001
pubmed: 29498927
Diabetes. 2016 May;65(5):1424-33
pubmed: 26861782
Andrology. 2016 Jul;4(4):662-72
pubmed: 27152447
Environ Int. 2019 Mar;124:130-138
pubmed: 30641256
J Investig Med. 2016 Feb;64(2):383-7
pubmed: 26911628
Environ Sci Pollut Res Int. 2015 Oct;22(19):14546-59
pubmed: 25854201
Nutrients. 2017 Oct 28;9(11):
pubmed: 29143791
Int J Environ Res Public Health. 2017 Oct 24;14(10):
pubmed: 29064461
Sci Total Environ. 2017 Dec 31;607-608:1304-1312
pubmed: 28738507
Diabetes. 2016 Aug;65(8):2311-21
pubmed: 27207556
Environ Pollut. 2018 Jan;232:73-79
pubmed: 28923343
Environ Res. 2013 Feb;121:95-103
pubmed: 23266098
Eur Cardiol. 2018 Aug;13(1):42-45
pubmed: 30310470
Diabetes Care. 2019 Sep;42(9):1824-1832
pubmed: 31296647
Metabolomics. 2019 Apr 8;15(4):60
pubmed: 30963292
Am J Cardiol. 2005 Aug 1;96(3):399-404
pubmed: 16054467
Environ Pollut. 2017 Oct;229:168-176
pubmed: 28599201
Environ Int. 2019 Feb;123:390-398
pubmed: 30622063
Environ Sci Technol. 2012 Dec 4;46(23):12960-7
pubmed: 23102093
Reprod Toxicol. 2012 Jul;33(4):546-551
pubmed: 22107727
Clin Chem. 2018 Aug;64(8):1203-1210
pubmed: 29945965
Am J Epidemiol. 2009 Nov 15;170(10):1268-78
pubmed: 19846564
Diabetes Care. 2016 May;39(5):833-46
pubmed: 27208380
Environ Sci Technol. 2011 Oct 1;45(19):8037-45
pubmed: 21469664
Environ Health Perspect. 2017 Oct 02;125(10):107001
pubmed: 28974480
Metabolites. 2017 Apr 14;7(2):
pubmed: 28420092
Environ Int. 2014 Sep;70:62-75
pubmed: 24932785

Auteurs

Susanna D Mitro (SD)

Population Health Sciences Program, Harvard University, Boston, MA, USA.

Jinxi Liu (J)

Department of Epidemiology and Biostatistics, Biostatistics Center and Milken Institute School of Public Health, George Washington University, Rockville, MD, USA.

Lindsay M Jaacks (LM)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Abby F Fleisch (AF)

Pediatric Endocrinology and Diabetes, Maine Medical Center and Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USA.

Paige L Williams (PL)

Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.

William C Knowler (WC)

National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA.

Blandine Laferrère (B)

New York Obesity Research Center, Division of Endocrinology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Wei Perng (W)

Department of Epidemiology, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, Colorado School of Public Health, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA.

George A Bray (GA)

Pennington Biomedical Research Center/Louisiana State University, Baton Rouge, LA, USA.

Amisha Wallia (A)

Division of Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Marie-France Hivert (MF)

Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA; Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA.

Emily Oken (E)

Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.

Tamarra M James-Todd (TM)

Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard T.H. Chan School of Public Health and Division of Women's Health, Department of Medicine, Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Marinella Temprosa (M)

Department of Epidemiology and Biostatistics, Biostatistics Center and Milken Institute School of Public Health, George Washington University, Rockville, MD, USA. Electronic address: dppmail@bsc.gwu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Per- and polyfluoroalkyl substance plasma...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Per- and polyfluoroalkyl substance plasma...
questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Polluants environnementaux › Per- and polyfluoroalkyl substance plasma...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Per- and polyfluoroalkyl substance plasma...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Métabolomique › Per- and polyfluoroalkyl substance plasma...
questionsmedicales.fr › Disciplines des sciences naturelles › Science › Recherche › Plan de recherche › Per- and polyfluoroalkyl substance plasma...